Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
US ˙ NasdaqCM ˙ US00653A1079

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Patrick J Kerins. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Patrick J Kerins har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:BZFD / BuzzFeed, Inc. 10% Owner 3.401.499
US:ZFOX / ZeroFox Holdings, Inc. 10% Owner 0
US:SGMT / Sagimet Biosciences Inc. 10% Owner 13.139
US:SYBX / Synlogic, Inc. 10% Owner 2.922.773
US:UTRS / Minerva Surgical, Inc. 10% Owner 34.437.052
US:OYST / Oyster Point Pharma Inc 10% Owner 0
US:PHAS / PhaseBio Pharmaceuticals Inc 10% Owner 4.857.525
US:IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF 10% Owner 2.611.050
US:CSPR / Casper Sleep Inc 10% Owner 0
US:COUR / Coursera, Inc. 10% Owner 70.394
US:SPT / Sprout Social, Inc. 10% Owner 38.644
US:NET / Cloudflare, Inc. 10% Owner 10.398.379
US:MRSN / Mersana Therapeutics, Inc. 10% Owner 3.594
US:ARDX / Ardelyx, Inc. 10% Owner 11.324
US:SURF / Surface Oncology Inc 10% Owner 2.892.877
US:RARX / Ra Pharmaceuticals, Inc. 10% Owner 0
US:CSBR / Champions Oncology, Inc. 10% Owner 0
10% Owner 4.270.691
US:GRTX / Galera Therapeutics, Inc. 10% Owner 0
US:TSRO / TESARO, Inc. 10% Owner 0
US:ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) 10% Owner 82.978.668
10% Owner 40.702
US:MULE / Mulesoft, Inc. 10% Owner 0
US:TCON / TRACON Pharmaceuticals, Inc. 10% Owner 707.964
US:TNTR / Tintri, Inc. 10% Owner 0
US:APPN / Appian Corporation 10% Owner 0
US:SBBP / Strongbridge Biopharma plc 10% Owner 8.282.616
US:CRCM / Care.com, Inc. 10% Owner 504
US:RYTM / Rhythm Pharmaceuticals, Inc. 10% Owner 0
US:ZSAN / Zosano Pharma Corp 10% Owner 952.809
US:ROKA / Roka Bioscience, Inc. 10% Owner 4.000
US:ILIU / Interleukin Genetics, Inc. 10% Owner 20.120.724
US:OPWR / Opower, Inc. 10% Owner 0
US:ECOM / ChannelAdvisor Corp Director 35.853
US:TRIV / TriVascular Technologies, Inc. 10% Owner 0
US:EPZM / Epizyme Inc 10% Owner 5.854.351
US:MM / Director 0
US:AVTX / Avalo Therapeutics, Inc. 10% Owner 0
US:HPTX / Hyperion Therapeutics Inc 10% Owner 0
US:BOX / Box, Inc. 10% Owner 2.091.457
US:TRVN / Trevena, Inc. 10% Owner 4.811.691
US:CVT / Cvent Holding Corp 10% Owner 1.009
US:DERM / Journey Medical Corporation 10% Owner 0
10% Owner 4.659.333
US:LOXO / Loxo Oncology, Inc. 10% Owner 0
10% Owner 0
US:GLYC / GlycoMimetics, Inc. 10% Owner 0
US:GRPN / Groupon, Inc. 10% Owner 7.944
Director, 10% Owner 0
US:CLVS / Clovis Oncology Inc 10% Owner 575
US:WDAY / Workday, Inc. 10% Owner 4.642.425
US:FIO / Franklin Income Opportunities Fund 10% Owner 0
US:ECHO / Echo Global Logistics Inc 10% Owner 97
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Patrick J Kerins. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insidersalg ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insiderkøb APPN / Appian Corporation – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APPN / Appian Corporation Insider Trades
Insidersalg APPN / Appian Corporation – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

APPN / Appian Corporation Insider Trades
Insiderkøb ARDX / Ardelyx, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2014-06-24 ARDX New Enterprise Associates 12, Limited Partnership 510.442 14,0000 510.442 14,0000 7.146.188 162 32.89 9.642.249 134,93

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ARDX / Ardelyx, Inc. Insider Trades
Insidersalg ARDX / Ardelyx, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ARDX / Ardelyx, Inc. Insider Trades
Insiderkøb AVTX / Avalo Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insidersalg AVTX / Avalo Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insiderkøb BOX / Box, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BOX / Box, Inc. Insider Trades
Insidersalg BOX / Box, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BOX / Box, Inc. Insider Trades
Insiderkøb BZFD / BuzzFeed, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BZFD / BuzzFeed, Inc. Insider Trades
Insidersalg BZFD / BuzzFeed, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BZFD / BuzzFeed, Inc. Insider Trades
Insiderkøb CSBR / Champions Oncology, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CSBR / Champions Oncology, Inc. Insider Trades
Insidersalg CSBR / Champions Oncology, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2020-03-06 CSBR New Enterprise Associates 14, L.P. 708.155 6,9900 708.155 6,9900 4.950.003 6 4.19 -1.982.834 -40,06

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CSBR / Champions Oncology, Inc. Insider Trades
Insiderkøb DERM / Journey Medical Corporation – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

DERM / Journey Medical Corporation Insider Trades
Insidersalg DERM / Journey Medical Corporation – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

DERM / Journey Medical Corporation Insider Trades
Insiderkøb GRPN / Groupon, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GRPN / Groupon, Inc. Insider Trades
Insidersalg GRPN / Groupon, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GRPN / Groupon, Inc. Insider Trades
Insiderkøb GRTX / Galera Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-11-12 GRTX New Enterprise Associates 14, L.P. 416.666 12,0000 416.666 12,0000 4.999.992 111 17.67 2.362.496 47,25

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insidersalg GRTX / Galera Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insiderkøb IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-03-16 IMRA New Enterprise Associates 14, L.P. 475.000 16,0000 118.750 64,0000 7.600.000 87 54.87 -1.084.188 -14,27

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF Insider Trades
Insidersalg IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2022-04-06 IMRA New Enterprise Associates 14, L.P. 255.463 1,1032 63.866 4,4128 281.827 6 0.9900 -218.600 -77,57
2022-04-05 IMRA New Enterprise Associates 14, L.P. 439.088 1,0691 109.772 4,2764 469.429
2022-01-25 IMRA New Enterprise Associates 14, L.P. 102.952 1,4745 25.738 5,8980 151.803
2022-01-24 IMRA New Enterprise Associates 14, L.P. 19.984 1,5521 4.996 6,2084 31.017
2022-01-21 IMRA New Enterprise Associates 14, L.P. 11.622 1,6683 2.906 6,6732 19.389
2022-01-20 IMRA New Enterprise Associates 14, L.P. 6.295 1,8086 1.574 7,2344 11.385
2022-01-19 IMRA New Enterprise Associates 14, L.P. 13.412 1,8203 3.353 7,2812 24.414
2022-01-18 IMRA New Enterprise Associates 14, L.P. 6.848 1,8877 1.712 7,5508 12.927
2022-01-14 IMRA New Enterprise Associates 14, L.P. 9.707 1,9144 2.427 7,6576 18.583
2022-01-13 IMRA New Enterprise Associates 14, L.P. 7.209 1,9262 1.802 7,7048 13.886
2022-01-12 IMRA New Enterprise Associates 14, L.P. 4.634 2,0193 1.158 8,0772 9.357
2022-01-11 IMRA New Enterprise Associates 14, L.P. 2.409 2,0421 602 8,1684 4.919
2022-01-10 IMRA New Enterprise Associates 14, L.P. 1.751 2,0000 438 8,0000 3.502
2022-01-07 IMRA New Enterprise Associates 14, L.P. 14.600 2,0766 3.650 8,3064 30.318
2022-01-06 IMRA New Enterprise Associates 14, L.P. 10.257 2,1649 2.564 8,6596 22.205
2022-01-05 IMRA New Enterprise Associates 14, L.P. 8.200 2,2487 2.050 8,9948 18.439
2022-01-04 IMRA New Enterprise Associates 14, L.P. 13.459 2,3437 3.365 9,3748 31.544
2022-01-03 IMRA New Enterprise Associates 14, L.P. 44.665 2,3373 11.166 9,3492 104.396
2021-12-31 IMRA New Enterprise Associates 14, L.P. 49.953 2,2503 12.488 9,0012 112.409
2021-12-30 IMRA New Enterprise Associates 14, L.P. 21.858 2,2905 5.464 9,1620 50.066
2021-12-29 IMRA New Enterprise Associates 14, L.P. 15.196 2,3002 3.799 9,2008 34.954
2021-12-28 IMRA New Enterprise Associates 14, L.P. 24.580 2,3409 6.145 9,3636 57.539
2021-12-27 IMRA New Enterprise Associates 14, L.P. 27.651 2,4233 6.913 9,6932 67.007
2021-12-23 IMRA New Enterprise Associates 14, L.P. 23.961 2,4100 5.990 9,6400 57.746
2021-12-22 IMRA New Enterprise Associates 14, L.P. 20.109 2,3213 5.027 9,2852 46.679
2021-12-21 IMRA New Enterprise Associates 14, L.P. 41.222 2,3241 10.306 9,2964 95.804
2021-12-20 IMRA New Enterprise Associates 14, L.P. 47.000 2,2103 11.750 8,8412 103.884
2021-12-20 IMRA New Enterprise Associates 14, L.P. 38.123 2,3272 9.531 9,3088 88.720
2021-12-16 IMRA New Enterprise Associates 14, L.P. 44.993 2,2347 11.248 8,9388 100.546
2021-12-15 IMRA New Enterprise Associates 14, L.P. 28.817 2,2794 7.204 9,1176 65.685
2021-12-14 IMRA New Enterprise Associates 14, L.P. 15.093 2,5603 3.773 10,2412 38.643
2021-12-13 IMRA New Enterprise Associates 14, L.P. 17.501 2,8317 4.375 11,3268 49.558
2021-12-10 IMRA New Enterprise Associates 14, L.P. 8.667 2,8316 2.167 11,3264 24.541
2021-12-09 IMRA New Enterprise Associates 14, L.P. 5.666 2,9462 1.416 11,7848 16.693

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF Insider Trades
Insiderkøb MRSN / Mersana Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-03-05 MRSN New Enterprise Associates 14, L.P. 3.750.000 4,0000 150.000 100,0000 15.000.000 358 9.2800 -13.608.000 -90,72

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insidersalg MRSN / Mersana Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2019-08-28 MRSN New Enterprise Associates 14, L.P. 1.211 2,9100 48 72,7500 3.524 40 1.4500 -3.454 -98,02

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insiderkøb SGMT / Sagimet Biosciences Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2023-07-18 SGMT NEW ENTERPRISE ASSOCIATES 13 LP 30.000 16,0000 30.000 16,0000 480.000 188 18.4200 72.600 15,12

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SGMT / Sagimet Biosciences Inc. Insider Trades
Insidersalg SGMT / Sagimet Biosciences Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2023-07-18 SGMT NEW ENTERPRISE ASSOCIATES 13 LP 662 16,0000 662 16,0000 10.592 118 2.2300 -9.116 -86,06

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SGMT / Sagimet Biosciences Inc. Insider Trades
Insiderkøb SPT / Sprout Social, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SPT / Sprout Social, Inc. Insider Trades
Insidersalg SPT / Sprout Social, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2020-08-17 SPT NEW ENTERPRISE ASSOCIATES 13 LP 2.992.910 27,5000 2.992.910 27,5000 82.305.025 0 31.49 11.941.711 14,51
2020-08-17 SPT NEW ENTERPRISE ASSOCIATES 13 LP 448.936 27,5000 448.936 27,5000 12.345.740

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SPT / Sprout Social, Inc. Insider Trades
Insiderkøb SYBX / Synlogic, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYBX / Synlogic, Inc. Insider Trades
Insidersalg SYBX / Synlogic, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SYBX / Synlogic, Inc. Insider Trades
Insiderkøb TRVN / Trevena, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2014-12-10 TRVN New Enterprise Associates 12, Limited Partnership 1.000.000 4,0000 40.000 100,0000 4.000.000 282 332.5 9.300.000 232,50
2014-02-05 TRVN New Enterprise Associates 12, Limited Partnership 472.410 7,0000 18.896 175,0000 3.306.870

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRVN / Trevena, Inc. Insider Trades
Insidersalg TRVN / Trevena, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRVN / Trevena, Inc. Insider Trades
Insiderkøb UTRS / Minerva Surgical, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2023-02-09 UTRS NEW ENTERPRISE ASSOCIATES 13 LP 24.437.927 0,2046 1.221.896 4,0920 5.000.000 4 9.6 6.730.203 134,60
2021-10-26 UTRS NEW ENTERPRISE ASSOCIATES 13 LP 1.300.000 12,0000 65.000 240,0000 15.600.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

UTRS / Minerva Surgical, Inc. Insider Trades
Insidersalg UTRS / Minerva Surgical, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

UTRS / Minerva Surgical, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Patrick J Kerins som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-03-14 2025-03-14 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -273.246 3.401.499 -7,44 2,26 -618.383 7.697.932
2025-03-14 2025-03-13 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -61.448 3.674.745 -1,64 2,01 -123.769 7.401.671
2025-03-14 2025-03-12 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -28.272 3.736.193 -0,75 1,98 -55.854 7.381.223
2025-03-11 2025-03-11 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -13.629 3.764.465 -0,36 1,95 -26.620 7.352.753
2025-03-11 2025-03-07 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -33.848 3.778.094 -0,89 2,06 -69.602 7.768.895
2025-03-06 2025-03-06 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -11.127 3.811.942 -0,29 2,10 -23.372 8.006.984
2025-03-06 2025-03-05 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -8.966 3.823.069 -0,23 2,04 -18.266 7.788.356
2025-03-06 2025-03-04 4 BZFD BuzzFeed, Inc.
Class A Common Stock
S - Sale -1.438 3.832.035 -0,04 2,07 -2.978 7.936.144
2024-05-15 2024-05-13 4 ZFOX ZeroFox Holdings, Inc.
Common Stock
U - Other -18.068.513 0 -100,00
2024-01-31 2024-01-29 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
J - Other 13.139 13.139
2024-01-31 2024-01-29 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
J - Other -260.950 0 -100,00
2024-01-31 2024-01-29 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
J - Other 260.950 260.950
2024-01-31 2024-01-29 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
J - Other -850.000 3.000.275 -22,08
2023-12-05 2023-12-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 29.034 222.847 14,98
2023-10-06 3 SYBX SYNLOGIC, INC.
Common Stock
2.922.773
2023-09-05 2023-09-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 29.033 193.813 17,62
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
P - Purchase 30.000 3.850.275 0,79 16,00 480.000 61.604.400
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
S - Sale -662 3.820.275 -0,02 16,00 -10.592 61.124.400
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
X - Other 13.404 3.820.937 0,35 0,79 10.653 3.036.881
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
C - Conversion 3.769.857 3.807.533 10.005,99
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Series A Common Stock
J - Other 37.676 37.676
2023-07-20 2023-07-18 4 SGMT Sagimet Biosciences Inc.
Common Stock
J - Other -37.676 0 -100,00
2023-07-13 3 SGMT Sagimet Biosciences Inc.
Common Stock
37.676
2023-06-06 2023-06-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 29.033 164.780 21,39
2023-04-06 2023-04-05 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 29.033 135.747 27,21
2023-02-10 2023-02-09 4 UTRS MINERVA SURGICAL INC
Common Stock
P - Purchase 24.437.927 34.437.052 244,40 0,20 5.000.000 7.045.821
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -5.925.287 0 -100,00
2022-12-06 2022-12-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 26.679 106.714 33,33
2022-10-26 2022-10-25 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
S - Sale -1.784.109 4.857.525 -26,86 0,15 -262.264 714.056
2022-09-06 2022-09-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 26.678 80.034 50,00
2022-08-05 3 ZFOX ZeroFox Holdings, Inc.
Common Stock
18.068.513
2022-06-07 2022-06-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 26.678 53.356 100,00
2022-04-07 2022-04-06 4 IMRA IMARA Inc.
Common Stock
S - Sale -255.463 2.611.050 -8,91 1,10 -281.827 2.880.510
2022-04-07 2022-04-05 4 IMRA IMARA Inc.
Common Stock
S - Sale -439.088 2.866.513 -13,28 1,07 -469.429 3.064.589
2022-03-07 2022-03-03 4 BZFD BuzzFeed, Inc.
Restricted Stock Units
M - Exercise -26.678 80.036 -25,00
2022-03-07 2022-03-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
M - Exercise 26.678 26.678
2022-02-24 2022-02-22 4 BZFD BuzzFeed, Inc.
Restricted Stock Units
A - Award 106.714 106.714
2022-01-26 2022-01-25 4 CSPR Casper Sleep Inc.
Common Stock
U - Other -6.222.502 0 -100,00 6,90 -42.935.264
2022-01-25 2022-01-25 4 IMRA IMARA Inc.
Common Stock
S - Sale -102.952 3.305.601 -3,02 1,47 -151.803 4.874.109
2022-01-25 2022-01-24 4 IMRA IMARA Inc.
Common Stock
S - Sale -19.984 3.408.553 -0,58 1,55 -31.017 5.290.415
2022-01-25 2022-01-21 4 IMRA IMARA Inc.
Common Stock
S - Sale -11.622 3.428.537 -0,34 1,67 -19.389 5.719.828
2022-01-20 2022-01-20 4 IMRA IMARA Inc.
Common Stock
S - Sale -6.295 3.440.159 -0,18 1,81 -11.385 6.221.872
2022-01-20 2022-01-19 4 IMRA IMARA Inc.
Common Stock
S - Sale -13.412 3.446.454 -0,39 1,82 -24.414 6.273.580
2022-01-20 2022-01-18 4 IMRA IMARA Inc.
Common Stock
S - Sale -6.848 3.459.866 -0,20 1,89 -12.927 6.531.189
2022-01-14 2022-01-14 4 IMRA IMARA Inc.
Common Stock
S - Sale -9.707 3.466.714 -0,28 1,91 -18.583 6.636.677
2022-01-14 2022-01-13 4 IMRA IMARA Inc.
Common Stock
S - Sale -7.209 3.476.421 -0,21 1,93 -13.886 6.696.282
2022-01-14 2022-01-12 4 IMRA IMARA Inc.
Common Stock
S - Sale -4.634 3.483.630 -0,13 2,02 -9.357 7.034.494
2022-01-11 2022-01-11 4 IMRA IMARA Inc.
Common Stock
S - Sale -2.409 3.488.264 -0,07 2,04 -4.919 7.123.384
2022-01-11 2022-01-10 4 IMRA IMARA Inc.
Common Stock
S - Sale -1.751 3.490.673 -0,05 2,00 -3.502 6.981.346
2022-01-11 2022-01-07 4 IMRA IMARA Inc.
Common Stock
S - Sale -14.600 3.492.424 -0,42 2,08 -30.318 7.252.368
2022-01-06 2022-01-06 4 IMRA IMARA Inc.
Common Stock
S - Sale -10.257 3.507.024 -0,29 2,16 -22.205 7.592.356
2022-01-06 2022-01-05 4 IMRA IMARA Inc.
Common Stock
S - Sale -8.200 3.517.281 -0,23 2,25 -18.439 7.909.310
2022-01-06 2022-01-04 4 IMRA IMARA Inc.
Common Stock
S - Sale -13.459 3.525.481 -0,38 2,34 -31.544 8.262.670
2022-01-03 2022-01-03 4 IMRA IMARA Inc.
Common Stock
S - Sale -44.665 3.538.940 -1,25 2,34 -104.396 8.271.564
2022-01-03 2021-12-31 4 IMRA IMARA Inc.
Common Stock
S - Sale -49.953 3.583.605 -1,37 2,25 -112.409 8.064.186
2022-01-03 2021-12-30 4 IMRA IMARA Inc.
Common Stock
S - Sale -21.858 3.633.558 -0,60 2,29 -50.066 8.322.665
2021-12-29 2021-12-29 4 IMRA IMARA Inc.
Common Stock
S - Sale -15.196 3.655.416 -0,41 2,30 -34.954 8.408.188
2021-12-29 2021-12-28 4 IMRA IMARA Inc.
Common Stock
S - Sale -24.580 3.670.612 -0,67 2,34 -57.539 8.592.536
2021-12-29 2021-12-27 4 IMRA IMARA Inc.
Common Stock
S - Sale -27.651 3.695.192 -0,74 2,42 -67.007 8.954.559
2021-12-27 2021-12-23 4 IMRA IMARA Inc.
Common Stock
S - Sale -23.961 3.722.843 -0,64 2,41 -57.746 8.972.052
2021-12-27 2021-12-22 4 IMRA IMARA Inc.
Common Stock
S - Sale -20.109 3.746.804 -0,53 2,32 -46.679 8.697.456
2021-12-27 2021-12-21 4 IMRA IMARA Inc.
Common Stock
S - Sale -41.222 3.766.913 -1,08 2,32 -95.804 8.754.683
2021-12-27 2021-12-20 4 IMRA IMARA Inc.
Common Stock
S - Sale -38.123 3.808.135 -0,99 2,33 -88.720 8.862.292
2021-12-27 2021-12-20 4 IMRA IMARA Inc.
Common Stock
S - Sale -47.000 3.846.258 -1,21 2,21 -103.884 8.501.384
2021-12-27 2021-12-16 4 IMRA IMARA Inc.
Common Stock
S - Sale -44.993 3.893.258 -1,14 2,23 -100.546 8.700.264
2021-12-27 2021-12-15 4 IMRA IMARA Inc.
Common Stock
S - Sale -28.817 3.938.251 -0,73 2,28 -65.685 8.976.849
2021-12-27 2021-12-14 4 IMRA IMARA Inc.
Common Stock
S - Sale -15.093 3.967.068 -0,38 2,56 -38.643 10.156.884
2021-12-27 2021-12-13 4 IMRA IMARA Inc.
Common Stock
S - Sale -17.501 3.982.161 -0,44 2,83 -49.558 11.276.285
2021-12-27 2021-12-10 4 IMRA IMARA Inc.
Common Stock
S - Sale -8.667 3.999.662 -0,22 2,83 -24.541 11.325.443
2021-12-27 2021-12-09 4 IMRA IMARA Inc.
Common Stock
S - Sale -5.666 4.008.329 -0,14 2,95 -16.693 11.809.339
2021-12-07 2021-12-03 4 BZFD BuzzFeed, Inc.
Class A Common Stock
A - Award 15.333.892 15.333.892
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion -3.503.021 0 -100,00
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 850.491 3.503.021 32,06
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 546.011 2.652.530 25,92
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 503.145 2.106.519 31,38
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 517.592 1.603.374 47,67
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 532.333 1.085.782 96,18
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion 553.449 553.449
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series D Preferred Stock
C - Conversion -3.409.709 0 -100,00
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note
C - Conversion 0
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series C Preferred Stock
C - Conversion -1.190.212 0 -100,00
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Series B Preferred Stock
C - Conversion -596.183 0 -100,00
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Common Stock
P - Purchase 1.300.000 9.999.125 14,94 12,00 15.600.000 119.989.500
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Common Stock
C - Conversion 3.503.021 8.699.125 67,42
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Common Stock
C - Conversion 3.409.709 5.196.104 190,87
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Common Stock
C - Conversion 1.190.212 1.786.395 199,64
2021-10-28 2021-10-26 4 UTRS MINERVA SURGICAL INC
Common Stock
C - Conversion 596.183 596.183
2021-05-21 2021-05-19 4 COUR Coursera, Inc.
Common Stock
J - Other 70.394 70.394
2021-05-21 2021-05-19 4 COUR Coursera, Inc.
Common Stock
J - Other -1.398.025 0 -100,00
2021-05-21 2021-05-19 4 COUR Coursera, Inc.
Common Stock
J - Other 1.398.025 1.398.025
2021-05-21 2021-05-19 4 COUR Coursera, Inc.
Common Stock
J - Other -4.553.828 13.661.886 -25,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series F Preferred Stock
C - Conversion -1.470.588 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series E Preferred Stock
C - Conversion -833.333 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series D Preferred Stock
C - Conversion -66.667 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series C Preferred Stock
C - Conversion -4.908.216 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series B Preferred Stock
C - Conversion -1.019.805 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Series A Preferred Stock
C - Conversion -9.590.105 0 -100,00
2021-04-05 2021-04-05 4 COUR Coursera, Inc.
Common Stock
C - Conversion 17.888.714 18.215.714 5.470,55
2021-03-30 3 COUR Coursera, Inc.
Common Stock
327.000
2020-11-17 2020-11-13 4 SPT Sprout Social, Inc.
Class A Common Stock
J - Other 38.644 38.644
2020-11-17 2020-11-13 4 SPT Sprout Social, Inc.
Class A Common Stock
J - Other -767.500 0 -100,00
2020-11-17 2020-11-13 4 SPT Sprout Social, Inc.
Class A Common Stock
J - Other 767.500 767.500
2020-11-17 2020-11-13 4 SPT Sprout Social, Inc.
Class A Common Stock
J - Other -2.500.000 3.082.854 -44,78
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class B Common Stock
C - Conversion -13.161.963 10.398.379 -55,86
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 203.454 203.454
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -4.040.723 0 -100,00
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 4.040.723 4.040.723
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -13.161.963 2.763.583 -82,65
2020-11-13 2020-11-11 4 NET Cloudflare, Inc.
Class A Common Stock
C - Conversion 13.161.963 15.925.546 476,26
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 372 3.594 11,55
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 830 3.222 34,70
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -10.000 0 -100,00
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 10.000 10.000
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -20.000 0 -100,00
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 20.000 20.000
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -2.000.000 5.959.520 -25,13
2020-08-18 2020-08-17 4 SPT Sprout Social, Inc.
Class A Common Stock
S - Sale -448.936 5.582.854 -7,44 27,50 -12.345.740 153.528.485
2020-08-18 2020-08-17 4 SPT Sprout Social, Inc.
Class A Common Stock
S - Sale -2.992.910 6.031.790 -33,16 27,50 -82.305.025 165.874.225
2020-08-18 2020-08-18 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -120.904 0 -100,00 40,03 -4.840.005
2020-08-18 2020-08-17 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -112.435 120.904 -48,19 39,50 -4.441.643 4.776.204
2020-08-18 2020-08-17 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -12.565 233.339 -5,11 38,68 -486.069 9.026.579
2020-08-13 2020-08-12 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -14.096 245.904 -5,42 40,00 -563.908 9.837.340
2020-08-13 2020-08-11 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -50.508 260.000 -16,27 37,79 -1.908.753 9.825.686
2020-08-10 2020-08-10 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -1.100 310.508 -0,35 38,91 -42.806 12.083.264
2020-08-10 2020-08-10 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -13.909 311.608 -4,27 37,77 -525.354 11.769.683
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class B Common Stock
C - Conversion -19.763.347 23.560.342 -45,62
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 325.517 325.517
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -6.465.156 0 -100,00
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 6.465.156 6.465.156
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -21.059.140 2.763.583 -88,40
2020-08-10 2020-08-07 4 NET Cloudflare, Inc.
Class A Common Stock
C - Conversion 19.763.347 23.822.723 486,86
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other 137 11.324 1,22
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other 121 11.187 1,09
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other 10.825 11.066 4.491,70
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other -455.222 0 -100,00
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other 455.222 455.222
2020-06-12 2020-06-10 4 ARDX ARDELYX, INC.
Common Stock
J - Other -1.482.809 8.086.401 -15,50
2020-05-22 2020-05-20 4 SURF Surface Oncology, Inc.
Common Stock
S - Sale -420.000 2.892.877 -12,68 3,66 -1.535.562 10.576.648
2020-05-21 2020-05-20 4 NET Cloudflare, Inc.
Class A Common Stock
S - Sale -81.376 0 -100,00 27,55 -2.241.901
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class B Common Stock
C - Conversion -5.264.785 43.323.689 -10,84
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 81.376 81.376
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -1.616.289 0 -100,00
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other 1.616.289 1.616.289
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class A Common Stock
J - Other -5.264.785 4.059.376 -56,46
2020-05-21 2020-05-19 4 NET Cloudflare, Inc.
Class A Common Stock
C - Conversion 5.264.785 9.324.161 129,69
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Stock Purchase Warrant (right to buy)
X - Other -70.593 0 -100,00
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Common Stock
S - Sale -1.211 11.959.520 -0,01 2,91 -3.524 34.802.203
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Common Stock
X - Other 70.593 11.960.731 0,59 0,05 3.530 598.037
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 745 2.392 45,23
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 1.647 1.647
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -20.000 0 -100,00
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 20.000 20.000
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -40.000 0 -100,00
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other 40.000 40.000
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock
J - Other -4.000.000 7.959.520 -33,45
2020-04-03 2020-04-02 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
D - Sale to Issuer -6.135.234 0 -100,00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series B Preferred Stock
C - Conversion -5.625.926 0 -100,00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series A Preferred Stock
C - Conversion -15.323.454 0 -100,00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series Seed Preferred Stock
C - Conversion -1.342.780 0 -100,00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Common Stock
P - Purchase 475.000 4.013.995 13,42 16,00 7.600.000 64.223.920
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Common Stock
C - Conversion 3.538.995 3.538.995
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Warrant to Purchase Common Stock (right to buy)
X - Other -859.375 0 -100,00
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock
S - Sale -708.155 1.713.720 -29,24 6,99 -4.950.003 11.978.903
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock
X - Other 859.375 2.421.875 55,00 5,76 4.950.000 13.950.000
2020-02-12 2020-02-10 4 CSPR Casper Sleep Inc.
Common Stock
P - Purchase 1.250.000 6.222.412 25,14 12,00 15.000.000 74.668.944
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock
9.944.824
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Series D Convertible Preferred Stock
C - Conversion -268.679 0 -100,00
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Series C Convertible Preferred Stock
C - Conversion -832.126 0 -100,00
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Series B-1 Convertible Preferred Stock
C - Conversion -1.837.275 0 -100,00
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Series B Convertible Preferred Stock
C - Conversion -6.086.620 0 -100,00
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Class A Common Stock
C - Conversion 268.679 9.024.700 3,07
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Class A Common Stock
C - Conversion 832.126 8.756.021 10,50
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Class A Common Stock
C - Conversion 1.837.275 7.923.895 30,19
2019-12-18 2019-12-17 4 SPT Sprout Social, Inc.
Class A Common Stock
C - Conversion 6.086.620 6.086.620
2019-12-09 2019-12-09 4 ARDX ARDELYX, INC.
Common Stock
A - Award 400.000 9.569.210 4,36 6,25 2.500.000 59.807.562
2019-11-29 2019-11-27 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
S - Sale -1.166.755 4.270.691 -21,46 2,52 -2.941.739 10.767.693
2019-11-29 2019-11-26 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
S - Sale -117.164 5.437.446 -2,11 2,45 -287.134 13.325.549
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.354.829 0 -100,00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -9.600.000 0 -100,00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -8.975.000 0 -100,00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
P - Purchase 416.666 4.358.047 10,57 12,00 4.999.992 52.296.564
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 267.935 3.941.381 7,29
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 1.898.524 3.673.446 106,96
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 1.774.922 1.774.922
2019-11-05 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
11.850.574
2019-11-05 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
11.850.574
2019-11-05 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
11.850.574
2019-09-18 2019-09-17 4 NET Cloudflare, Inc.
Class B Common Stock
C - Conversion 42.463.920 48.588.474 693,34
2019-09-18 2019-09-17 4 NET Cloudflare, Inc.
Series D Convertible Preferred Stock
C - Conversion -4.059.376 0 -100,00
2019-09-18 2019-09-17 4 NET Cloudflare, Inc.
Series C Convertible Preferred Stock
C - Conversion -7.183.310 0 -100,00
2019-09-18 2019-09-17 4 NET Cloudflare, Inc.
Series B Convertible Preferred Stock
C - Conversion -35.280.610 0 -100,00
2019-09-18 2019-09-17 4 NET Cloudflare, Inc.
Class A Common Stock
C - Conversion 4.059.376 4.059.376
2019-03-06 2019-03-05 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 3.750.000 11.890.138 46,07 4,00 15.000.000 47.560.552
2019-01-22 2019-01-22 4 TSRO TESARO, Inc.
Common Stock
U - Other -1.333 0 -100,00 75,00 -99.975
2019-01-22 2019-01-22 4 TSRO TESARO, Inc.
Common Stock
U - Other -9.681.038 0 -100,00 75,00 -726.077.850
2018-12-14 2018-12-14 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
P - Purchase 645.161 6.135.234 11,75 15,50 9.999.996 95.096.127
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -1.124.301 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -437.706 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -4.349 437.706 -0,98 5,00 -21.745 2.188.530
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 181.190 442.055 69,46 0,12 21.743 53.047
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -181.190 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -3.279.627 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -1.177 3.279.627 -0,04 5,00 -5.885 16.398.135
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 49.030 3.280.804 1,52 0,12 5.884 393.696
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -49.030 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 1.800.000 6.641.634 37,18 5,00 9.000.000 33.208.170
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 4.841.634 4.841.634
2018-09-10 2018-09-07 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 3.000.000 82.978.668 3,75 1,67 5.000.100 138.300.546
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Warrant to purchase Common Stock
J - Other 40.702 40.702
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Warrant to purchase Series D Preferred Stock
J - Other -684.911 0 -100,00
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Series D Preferred Stock
C - Conversion -16.502.833 0 -100,00
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Series C Preferred Stock
C - Conversion -3.337.206 0 -100,00
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Series B Preferred Stock
C - Conversion -3.645.307 0 -100,00
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Common Stock
P - Purchase 545.455 2.484.870 28,12 11,00 6.000.005 27.333.570
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Common Stock
C - Conversion 980.715 1.939.415 102,30
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Common Stock
C - Conversion 432.033 958.700 82,03
2018-08-01 2018-07-30 4 LQDA Liquidia Technologies Inc
Common Stock
C - Conversion 515.547 526.667 4.636,21
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-07-25 3 LQDA Liquidia Technologies Inc
Common Stock
22.240
2018-05-30 2018-05-25 4 ARDX ARDELYX, INC.
Common Stock
A - Award 416.667 9.169.210 4,76 4,00 1.666.668 36.676.840
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class B Common Stock
C - Conversion -12.679.970 0 -100,00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock
U - Other -12.679.970 0 -100,00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock
C - Conversion 12.679.970 12.679.970
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Series A Preferred Stock
C - Conversion -6.995.000 0 -100,00
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Common Stock
P - Purchase 133.333 3.312.877 4,19 15,00 1.999.995 49.693.155
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Common Stock
C - Conversion 3.179.544 3.179.544
2018-03-28 2018-03-27 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 6.000.000 79.978.672 8,11 1,92 11.500.200 153.295.121
2018-03-28 2018-03-26 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 571.164 73.978.672 0,78 1,90 1.087.553 140.862.789
2018-03-27 2018-03-27 4 TCON Tracon Pharmaceuticals, Inc.
Warrant to Purchase Common Stock
P - Purchase 707.964 707.964 0,12 88.496 88.496
2018-03-27 2018-03-27 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
P - Purchase 707.964 3.466.003 25,67 2,70 1.911.503 9.358.208
2018-03-23 2018-03-23 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 294.090 73.407.508 0,40 1,95 572.358 142.865.692
2018-03-23 2018-03-22 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 869.574 73.113.418 1,20 1,90 1.655.669 139.207.948
2018-03-23 2018-03-21 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 104.844 72.243.844 0,15 1,81 189.820 130.797.480
2018-03-06 2018-03-06 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 12.634 9.681.129 0,13 59,82 755.708 579.080.604
2018-03-06 2018-03-05 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 17.248 9.668.495 0,18 59,76 1.030.813 577.829.869
2018-03-06 2018-03-05 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 1.600 9.651.247 0,02 59,15 94.634 570.832.655
2018-03-06 2018-03-05 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 30.321 9.649.647 0,32 58,28 1.767.153 562.395.902
2018-03-06 2018-03-02 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 17.859 9.619.326 0,19 57,34 1.024.114 551.614.478
2018-03-06 2018-03-02 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 4.080 9.601.467 0,04 56,66 231.174 544.022.961
2018-03-06 2018-03-02 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 6.399 9.597.387 0,07 55,01 352.005 527.946.500
2018-03-06 2018-03-02 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 26.304 9.590.988 0,28 54,32 1.428.875 520.997.814
2018-03-02 2018-02-26 4 TNTR Tintri, Inc.
Note Purchase Agreement (obligation to purchase)
E - Other 0
2018-02-21 2018-02-16 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
P - Purchase 2.000.000 5.490.073 57,31 6,00 12.000.000 32.940.438
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class B Common Stock
C - Conversion -2.724.202 0 -100,00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other 509 1.523 50,20
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other 1.014 1.014
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other -13.621 0 -100,00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other 13.621 13.621
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other -27.242 0 -100,00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other 27.242 27.242
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
J - Other -2.724.202 0 -100,00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock
C - Conversion 2.724.202 2.724.202
2018-01-26 2018-01-26 4 SYBX SYNLOGIC, INC.
Common Stock
A - Award 410.000 4.228.940 10,74 9,75 3.997.500 41.232.165
2018-01-09 3 SBBP Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value
8.282.616
2018-01-09 3 SBBP Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value
8.282.616
2017-12-19 2017-12-18 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
P - Purchase 2.000.000 5.554.610 56,26 5,00 10.000.000 27.773.050
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class B Common Stock
C - Conversion -569.620 2.724.202 -17,29
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class A Common Stock
S - Sale -569.620 0 -100,00 19,49 -11.101.894
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class A Common Stock
C - Conversion 569.620 569.620
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class B Common Stock
C - Conversion -2.820.516 3.293.822 -46,13
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class A Common Stock
S - Sale -2.820.516 0 -100,00 19,49 -54.971.857
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class A Common Stock
C - Conversion 2.820.516 2.820.516
2017-11-08 2017-11-06 4 CRCM Care.com Inc
Common Stock
J - Other 504 504
2017-11-08 2017-11-06 4 CRCM Care.com Inc
Common Stock
J - Other -10.000 0 -100,00
2017-11-08 2017-11-06 4 CRCM Care.com Inc
Common Stock
J - Other 10.000 10.000
2017-11-08 2017-11-06 4 CRCM Care.com Inc
Common Stock
J - Other -1.000.000 2.256.013 -30,71
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock
C - Conversion -2.927.708 0 -100,00
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stoc
C - Conversion -1.402.870 0 -100,00
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
P - Purchase 550.000 4.909.956 12,61 17,00 9.350.000 83.469.252
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
C - Conversion 2.927.708 4.359.956 204,41
2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
C - Conversion 1.402.870 1.432.248 4.775,24
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-08-30 2017-08-28 4 SYBX SYNLOGIC, INC.
Common Stock
A - Award 3.394.439 3.818.940 799,63
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series C-1 Preferred Stock
C - Conversion -2.216.626 0 -100,00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series B-1 Preferred Stock
C - Conversion -18.001.419 0 -100,00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series A-1 Preferred Stock
C - Conversion -11.931.173 0 -100,00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 1.000.000 8.140.138 14,01 15,00 15.000.000 122.102.070
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Common Stock
C - Conversion 7.140.138 7.140.138
2017-05-31 2017-05-31 4 APPN APPIAN CORP
Class B Common Stock
C - Conversion 6.114.338 6.114.338
2017-05-31 2017-05-31 4 APPN APPIAN CORP
Series B Convertible Preferred Stock
C - Conversion -6.114.338 0 -100,00
2017-03-28 2017-03-27 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
P - Purchase 12.870.000 72.139.000 21,71 0,70 9.009.000 50.497.300
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Class B Common Stock
J - Other 12.679.970 12.679.970
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series G Preferred Stock
C - Conversion -605.668 0 -100,00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series F Preferred Stock
C - Conversion -2.064.048 0 -100,00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series E Preferred Stock
C - Conversion -8.000.038 0 -100,00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series A Preferred Stock
C - Conversion -1.689.436 0 -100,00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock
J - Other -12.679.970 0 -100,00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock
C - Conversion 12.359.190 12.679.970 3.852,86
2017-03-16 3 MULE MULESOFT, INC
Common Stock
641.560
2017-03-16 3 MULE MULESOFT, INC
Common Stock
641.560
2017-02-14 2017-02-13 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -1.099.996 952.809 -53,59 2,01 -2.211.432 1.915.527
2016-11-29 2016-11-29 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
P - Purchase 869.565 2.758.039 46,05 5,75 4.999.999 15.858.724
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Series B-2 Preferred Stock
C - Conversion -4.362.472 0 -100,00
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Series B-1 Preferred Stock
C - Conversion -4.689.657 0 -100,00
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Series A Preferred Stock
C - Conversion -12.447.605 0 -100,00
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Warrants to Purchase Common Stock
X - Other -80.658 0 -100,00
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
P - Purchase 338.462 3.490.073 10,74 13,00 4.400.006 45.370.949
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
C - Conversion 623.210 3.151.611 24,65
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
C - Conversion 669.951 2.528.401 36,05
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
C - Conversion 1.778.227 1.858.450 2.216,60
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
S - Sale -435 80.223 -0,54 13,00 -5.655 1.042.899
2016-10-31 2016-10-31 4 RARX Ra Pharmaceuticals, Inc.
Common Stock
X - Other 80.658 80.658 0,07 5.646 5.646
2016-09-30 2016-09-21 4/A ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock
P - Purchase 4.000 4.000
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Warrant to Purchase Common Stock (right to buy)
P - Purchase 5.714.286 5.714.286
2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock
P - Purchase 4.000 4.000
2016-09-20 2016-09-16 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -7.471 2.052.805 -0,36 0,75 -5.603 1.539.604
2016-09-15 2016-09-13 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -10.000 2.060.276 -0,48 0,74 -7.400 1.524.604
2016-09-15 2016-09-14 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
P - Purchase 461.538 3.554.610 14,92 13,00 5.999.994 46.209.930
2016-08-31 2016-08-29 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -50.000 2.070.276 -2,36 1,01 -50.440 2.088.494
2016-08-26 2016-08-24 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -1.200 2.120.276 -0,06 1,21 -1.452 2.565.534
2016-08-02 2016-07-29 4 ILIU INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy)
P - Purchase 20.120.724 20.120.724
2016-08-02 2016-07-29 4 ILIU INTERLEUKIN GENETICS INC
Common Stock
P - Purchase 20.120.724 55.418.811 57,00 0,10 2.000.000 5.508.630
2016-07-21 2016-07-21 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -8.989 2.121.476 -0,42 1,33 -11.957 2.821.987
2016-07-21 2016-07-20 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -14.158 2.130.465 -0,66 1,24 -17.550 2.640.924
2016-07-21 2016-07-19 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -534 2.144.623 -0,02 1,17 -625 2.509.209
2016-07-20 2016-07-18 4 ARDX ARDELYX, INC.
Common Stock
P - Purchase 763.650 8.752.543 9,56 8,73 6.666.664 76.409.700
2016-07-15 2016-07-13 4 ZSAN Zosano Pharma Corp
Common Stock
S - Sale -13.382 2.145.157 -0,62 1,20 -16.060 2.574.403
2016-06-14 2016-06-14 4 OPWR OPOWER, INC.
Common Stock
U - Other -8.989.766 0 -100,00 10,30 -92.594.590
2016-03-18 2016-03-18 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 710.429 9.564.684 8,02 35,19 24.999.997 336.581.230
2016-03-01 2016-03-01 4 ECOM CHANNELADVISOR CORP
Common Stock
A - Award 13.761 35.853 62,29
2016-02-17 2016-02-17 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Series B Convertible Redeemable Preferred Stock
C - Conversion -4.423.723 0 -100,00
2016-02-17 2016-02-17 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Series A Convertible Redeemable Preferred Stock
C - Conversion -13.848.000 0 -100,00
2016-02-17 2016-02-17 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
P - Purchase 900.324 3.093.072 41,06 8,00 7.202.592 24.744.576
2016-02-17 2016-02-17 4 PTI PROTEOSTASIS THERAPEUTICS, INC.
Common Stock
C - Conversion 2.192.748 2.192.748
2016-02-04 2016-02-03 4 TRIV TriVascular Technologies, Inc.
Common Stock
D - Sale to Issuer -3.943.269 0 -100,00
2016-01-14 2016-01-13 4 ARDX ARDELYX, INC.
Common Stock
P - Purchase 500.000 7.988.893 6,68 10,00 5.000.000 79.888.930
2016-01-12 2016-01-12 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 1.111.111 5.854.351 23,43 9,00 9.999.999 52.689.159
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
118.538.000
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share
118.538.000
2015-12-15 2015-12-14 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -37.028 0 -100,00 13,32 -493.306
2015-12-11 2015-12-11 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -37.540 37.028 -50,34 13,25 -497.458 490.673
2015-12-11 2015-12-10 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -35.146 74.568 -32,03 13,53 -475.536 1.008.927
2015-12-11 2015-12-09 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -47.590 109.714 -30,25 13,41 -638.363 1.471.682
2015-12-08 2015-12-08 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -55.100 157.304 -25,94 13,26 -730.461 2.085.379
2015-12-08 2015-12-07 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -23.591 212.404 -10,00 13,10 -308.948 2.781.643
2015-12-08 2015-12-04 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -28.786 235.995 -10,87 13,08 -376.613 3.087.570
2015-12-03 2015-12-03 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -19.698 264.781 -6,92 13,14 -258.745 3.478.057
2015-12-03 2015-12-02 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -33.101 284.479 -10,42 13,25 -438.482 3.768.436
2015-12-03 2015-12-01 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -30.327 317.580 -8,72 13,11 -397.450 4.162.045
2015-11-30 2015-11-30 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -32.135 347.907 -8,46 13,17 -423.314 4.582.979
2015-11-30 2015-11-27 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -18.636 380.042 -4,67 13,24 -246.785 5.032.668
2015-11-30 2015-11-25 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -25.148 398.678 -5,93 13,22 -332.469 5.270.722
2015-11-24 2015-11-24 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -16.816 423.826 -3,82 13,23 -222.405 5.605.438
2015-11-24 2015-11-23 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -32.202 440.642 -6,81 13,59 -437.677 5.989.030
2015-11-24 2015-11-20 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -49.387 472.844 -9,46 13,39 -661.149 6.330.010
2015-11-20 2015-11-19 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -12.623 522.231 -2,36 13,46 -169.945 7.030.848
2015-11-20 2015-11-18 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -21.838 534.854 -3,92 13,63 -297.720 7.291.718
2015-10-23 2015-10-22 4 MM Millennial Media Inc.
Common Stock
U - Other -8.196.614 0 -100,00 1,75 -14.344.074
2015-10-23 2015-10-22 4 MM Millennial Media Inc.
Common Stock
U - Other -75.229 15.625 -82,80 1,75 -131.651 27.344
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Series B Convertible Preferred Stock
C - Conversion -16.638.880 0 -100,00
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Common Stock
C - Conversion 594.245 594.245
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock
P - Purchase 857.142 2.971.517 40,54 7,00 5.999.994 20.800.619
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock
J - Other 31.650 2.114.375 1,52
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock
J - Other 257.516 1.499.166 20,74
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Series D Preferred Stock
C - Conversion -583.559 0 -100,00
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.241.650 0 -100,00
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Common Stock
C - Conversion 583.559 2.082.725 38,93
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Common Stock
C - Conversion 1.241.650 1.241.650
2015-07-01 2015-07-01 4 ECOM CHANNELADVISOR CORP
Common Stock
A - Award 12.987 22.092 142,64
2015-06-09 2015-06-05 4 ARDX ARDELYX, INC.
Common Stock Warrant (right to buy)
P - Purchase 560.748 560.748 0,12 70.094 70.094
2015-06-09 2015-06-05 4 ARDX ARDELYX, INC.
Common Stock
P - Purchase 1.869.159 7.488.893 33,26 10,70 20.000.001 80.131.155
2015-06-02 2015-06-01 4 TSRO TESARO, Inc.
Common Stock
J - Other 504 1.333 60,80
2015-06-02 2015-06-01 4 TSRO TESARO, Inc.
Common Stock
J - Other -10.000 0 -100,00
2015-06-02 2015-06-01 4 TSRO TESARO, Inc.
Common Stock
J - Other 10.000 10.000
2015-06-02 2015-06-01 4 TSRO TESARO, Inc.
Common Stock
J - Other -1.000.000 8.854.255 -10,15
2015-05-11 2015-05-07 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
U - Other -120 0 -100,00 46,00 -5.520
2015-05-11 2015-05-07 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
U - Other -2.384.221 0 -100,00 46,00 -109.674.166
2015-03-24 3 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock
37.500.000
2015-03-24 3 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock
37.500.000
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Series B Redeemable Convertible Preferred Stock
C - Conversion -5.373.396 0 -100,00
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
P - Purchase 500.000 1.888.474 36,01 10,00 5.000.000 18.884.740
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
C - Conversion 1.388.474 1.388.474
2015-02-02 2015-01-30 4 ZSAN Zosano Pharma Corp
8% Convertible Note Issued 9/9/2013
C - Conversion
2015-02-02 2015-01-30 4 ZSAN Zosano Pharma Corp
8% Convertible Note Issued 12/2/2014
C - Conversion
2015-02-02 2015-01-30 4 ZSAN Zosano Pharma Corp
8% Convertible Note Issued 2/26/14
C - Conversion
2015-02-02 2015-01-30 4 ZSAN Zosano Pharma Corp
Common Stock
P - Purchase 23.457 2.158.539 1,10 11,00 258.027 23.743.929
2015-02-02 2015-01-30 4 ZSAN Zosano Pharma Corp
Common Stock
C - Conversion 341.201 2.135.082 19,02 9,35 3.190.229 19.963.017
2015-01-29 2015-01-28 4 BOX BOX INC
Class B Common Stock
J - Other 2.091.457 2.091.457
2015-01-29 2015-01-28 4 BOX BOX INC
Series E Preferred Stock
C - Conversion -274.916 0 -100,00
2015-01-29 2015-01-28 4 BOX BOX INC
Series D2 Preferred Stock
C - Conversion -1.653.761 0 -100,00
2015-01-29 2015-01-28 4 BOX BOX INC
Existing Class A Common Stock
J - Other -2.091.457 0 -100,00
2015-01-29 2015-01-28 4 BOX BOX INC
Existing Class A Common Stock
C - Conversion 1.928.677 2.091.457 1.184,84
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-26 3 ZSAN Zosano Pharma Corp
Common Stock
3.587.762
2015-01-22 3 BOX BOX INC
Existing Class A Common Stock
325.560
2015-01-22 3 BOX BOX INC
Existing Class A Common Stock
325.560
2015-01-05 2015-01-01 4 MM Millennial Media Inc.
Common Stock
A - Award 62.500 90.854 220,43
2014-12-29 2014-12-23 4 ARDX ARDELYX, INC.
Common Stock
J - Other -10.000 0 -100,00
2014-12-29 2014-12-23 4 ILIU INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy)
P - Purchase 19.868.965 19.868.965
2014-12-29 2014-12-23 4 ILIU INTERLEUKIN GENETICS INC
Common Stock
P - Purchase 19.868.965 35.298.087 128,78 0,10 1.992.857 3.540.398
2014-12-29 2014-12-23 4 ARDX ARDELYX, INC.
Common Stock
J - Other 241 241
2014-12-29 2014-12-23 4 ARDX ARDELYX, INC.
Common Stock
J - Other -10.000 0 -100,00
2014-12-16 2014-12-12 4 ARDX ARDELYX, INC.
Common Stock
J - Other -1.000.000 5.619.734 -15,11
2014-12-10 2014-12-10 4 TRVN TREVENA INC
Common Stock
P - Purchase 1.000.000 4.811.691 26,24 4,00 4.000.000 19.246.764
2014-11-28 2014-11-25 4 CVT CVENT INC
Common Stock
J - Other 504 1.009 99,80
2014-11-28 2014-11-25 4 CVT CVENT INC
Common Stock
J - Other -10.000 0 -100,00
2014-11-28 2014-11-25 4 CVT CVENT INC
Common Stock
J - Other 10.000 10.000
2014-11-28 2014-11-25 4 CVT CVENT INC
Common Stock
J - Other -1.000.000 3.994.106 -20,02
2014-10-08 2014-10-08 4 DERM Dermira, Inc.
Series C Preferred Stock
C - Conversion -382.840 0 -100,00
2014-10-08 2014-10-08 4 DERM Dermira, Inc.
Series B Preferred Stock
C - Conversion -655.321 0 -100,00
2014-10-08 2014-10-08 4 DERM Dermira, Inc.
Series A Preferred Stock
C - Conversion -2.378.408 0 -100,00
2014-10-08 2014-10-08 4 DERM Dermira, Inc.
Common Stock
P - Purchase 69.112 3.502.922 2,01 16,00 1.105.792 56.046.752
2014-10-08 2014-10-08 4 DERM Dermira, Inc.
Common Stock
C - Conversion 3.416.569 3.433.810 19.816,54
2014-10-02 3 DERM Dermira, Inc.
Common Stock
34.482
2014-10-02 3 DERM Dermira, Inc.
Common Stock
34.482
2014-08-29 2014-08-29 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale -11.600 4.659.333 -0,25 7,51 -87.070 34.972.953
2014-08-29 2014-08-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale -146.800 4.670.933 -3,05 7,87 -1.154.846 36.745.296
2014-08-29 2014-08-27 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale -108.300 4.817.733 -2,20 8,17 -884.811 39.360.879
2014-08-18 2014-08-14 4 EPZM Epizyme, Inc.
Common Stock
J - Other 651 651
2014-08-18 2014-08-14 4 EPZM Epizyme, Inc.
Common Stock
J - Other -12.900 0 -100,00
2014-08-18 2014-08-14 4 EPZM Epizyme, Inc.
Common Stock
J - Other 12.900 12.900
2014-08-18 2014-08-14 4 EPZM Epizyme, Inc.
Common Stock
J - Other -1.290.000 4.743.240 -21,38
2014-08-18 2014-08-14 4 CVT CVENT INC
Common Stock
J - Other 505 505
2014-08-18 2014-08-14 4 CVT CVENT INC
Common Stock
J - Other -10.000 0 -100,00
2014-08-18 2014-08-14 4 CVT CVENT INC
Common Stock
J - Other 10.000 10.000
2014-08-18 2014-08-14 4 CVT CVENT INC
Common Stock
J - Other -1.000.000 4.994.106 -16,68
2014-08-12 2014-08-12 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale -35.540 4.926.033 -0,72 6,76 -240.190 33.291.609
2014-08-12 2014-08-08 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale -675.000 4.961.573 -11,98 6,62 -4.468.568 32.846.109
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.558.651 0 -100,00
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock
P - Purchase 230.769 1.789.420 14,81 13,00 2.999.997 23.262.460
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock
C - Conversion 1.558.651 1.558.651
2014-08-05 2014-08-01 4 ECOM CHANNELADVISOR CORP
Common Stock
A - Award 2.680 9.105 41,71 25,00 67.000 227.625
2014-08-05 2014-08-01 4 ECOM CHANNELADVISOR CORP
Common Stock
A - Award 6.000 6.425 1.411,76
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Series E Preferred Stock
C - Conversion -5.987.892 0 -100,00
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Series D Preferred Stock
C - Conversion -8.555.784 0 -100,00
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Series C Preferred Stock
C - Conversion -4.030.224 0 -100,00
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Series B Preferred Stock
C - Conversion -12.360.000 0 -100,00
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock
P - Purchase 383.333 3.216.810 13,53 12,00 4.599.996 38.601.720
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock
C - Conversion 542.381 2.833.477 23,67
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock
C - Conversion 801.741 2.291.096 53,83
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock
C - Conversion 365.056 1.489.355 32,47
2014-07-22 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock
C - Conversion 1.119.565 1.124.299 23.649,45
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock
9.468
2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock
9.468
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
C - Conversion -72.190 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
J - Other -468 72.190 -0,64 14,00 -6.552 1.010.660
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
X - Other 72.658 72.658
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock Purchase Warrant
X - Other -72.658 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
C - Conversion -216.573 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
J - Other -1.402 216.573 -0,64 14,00 -19.628 3.032.022
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
X - Other 217.975 217.975
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock Purchase Warrant
X - Other -217.975 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series B Preferred Stock
C - Conversion -4.404.887 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Series A Preferred Stock
C - Conversion -1.415.642 0 -100,00
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Common Stock
P - Purchase 510.442 6.619.734 8,36 14,00 7.146.188 92.676.276
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Common Stock
C - Conversion 72.190 6.109.292 1,20
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Common Stock
C - Conversion 216.573 6.037.102 3,72
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Common Stock
C - Conversion 4.404.887 5.820.529 311,16
2014-06-26 2014-06-24 4 ARDX ARDELYX, INC.
Common Stock
C - Conversion 1.415.642 1.415.642
2014-06-06 2014-06-05 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
J - Other 120 120
2014-06-06 2014-06-05 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
J - Other -5.000 0 -100,00
2014-06-06 2014-06-05 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
J - Other 5.000 5.000
2014-06-06 2014-06-05 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
J - Other -500.000 2.384.221 -17,34
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (right to buy)
C - Conversion 55.831 55.831
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (right to buy)
C - Conversion -55.831 0 -100,00 15,81 -882.470
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series E Preferred Stock
C - Conversion -411.234 0 -100,00
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series D Preferred Stock
C - Conversion -1.236.487 0 -100,00
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series C Preferred Stock
C - Conversion -531.758 0 -100,00
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series B Preferred Stock
C - Conversion -383.249 0 -100,00
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series A Preferred Stock
C - Conversion -797.208 0 -100,00
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 411.234 3.943.269 11,64
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 1.236.487 3.532.035 53,86
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 531.758 2.295.548 30,15
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 383.249 1.763.790 27,76
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 797.208 1.380.541 136,66
2014-04-24 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
P - Purchase 583.333 583.333 12,00 6.999.996 6.999.996
2014-04-09 2014-04-09 4 OPWR OPOWER, INC.
Series C Preferred Stock
C - Conversion -1.123.596 0 -100,00
2014-04-09 2014-04-09 4 OPWR OPOWER, INC.
Series B Preferred Stock
C - Conversion -7.866.170 0 -100,00
2014-04-09 2014-04-09 4 OPWR OPOWER, INC.
Common Stock
C - Conversion 8.989.766 8.989.766
2014-04-03 2014-04-02 4 HIVE AEROHIVE NETWORKS, INC
Series E Preferred Stock
C - Conversion -1.065.143 0 -100,00
2014-04-03 2014-04-02 4 HIVE AEROHIVE NETWORKS, INC
Series D Preferred Stock
C - Conversion -3.588.446 0 -100,00
2014-04-03 2014-04-02 4 HIVE AEROHIVE NETWORKS, INC
Common Stock
C - Conversion 4.653.589 4.673.589 23.267,94
2014-03-27 3 HIVE AEROHIVE NETWORKS, INC
Common Stock
40.000
2014-03-27 3 HIVE AEROHIVE NETWORKS, INC
Common Stock
40.000
2014-03-11 2014-03-07 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 145 425 51,79
2014-03-11 2014-03-07 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -6.000 0 -100,00
2014-03-11 2014-03-07 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 6.000 6.000
2014-03-11 2014-03-07 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -600.000 556.692 -51,87
2014-02-21 2014-02-20 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 140 280 100,00
2014-02-21 2014-02-20 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -5.800 0 -100,00
2014-02-21 2014-02-20 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 5.800 5.800
2014-02-21 2014-02-20 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -580.000 1.156.692 -33,40
2014-02-11 2014-02-10 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 140 140
2014-02-11 2014-02-10 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -5.800 0 -100,00
2014-02-11 2014-02-10 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other 5.800 5.800
2014-02-11 2014-02-10 4 ECOM CHANNELADVISOR CORP
Common Stock
J - Other -580.000 1.736.692 -25,04
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series C Preferred Stock
C - Conversion -4.840.686 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
C - Conversion -1.462.857 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
S - Sale -487.143 1.462.857 -24,98 1,13 -549.984 1.651.566
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
X - Other 550.000 1.950.000 39,29 1,00 550.000 1.950.000
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Warrants
X - Other -550.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B Preferred Stock
C - Conversion -8.400.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series A Preferred Stock
C - Conversion -6.000.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
P - Purchase 472.410 3.811.691 14,15 7,00 3.306.870 26.681.837
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
C - Conversion 3.339.281 3.339.281
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Series E Convertible Preferred Stock
C - Conversion -612.089 0 -100,00
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Series D Convertible Preferred Stock
C - Conversion -401.837 0 -100,00
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Series C Convertible Preferred Stock
C - Conversion -2.242.087 0 -100,00
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Common Stock
C - Conversion 612.089 3.256.013 23,15
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Common Stock
C - Conversion 401.837 2.643.924 17,92
2014-01-29 2014-01-29 4 CRCM Care.com Inc
Common Stock
C - Conversion 2.242.087 2.242.087
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock Warrant (right to buy)
X - Other -56.983 0 -100,00
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock Warrant (right to buy)
X - Other -160.672 0 -100,00
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock Warrant (right to buy)
X - Other -749.721 0 -100,00
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
D - Sale to Issuer -13.551 2.316.692 -0,58 10,96 -148.519 25.390.944
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
X - Other 56.983 2.330.243 2,51 10,96 624.534 25.539.463
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
D - Sale to Issuer -38.210 2.273.260 -1,65 10,96 -418.782 24.914.930
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
X - Other 160.672 2.311.470 7,47 10,96 1.760.965 25.333.711
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
D - Sale to Issuer -260.280 2.150.798 -10,80 16,00 -4.164.480 34.412.768
2014-01-28 2014-01-27 4 ECOM CHANNELADVISOR CORP
Common Stock
X - Other 749.721 2.411.078 45,13 16,00 11.995.536 38.577.248
2014-01-23 2014-01-21 4 CVT CVENT INC
Common Stock
S - Sale -169.887 5.994.106 -2,76 35,50 -6.030.988 212.790.763
2014-01-21 2014-01-16 4 CVT CVENT INC
Common Stock
S - Sale -1.132.589 6.163.993 -15,52 35,50 -40.206.910 218.821.752
2014-01-15 2014-01-15 4 GLYC GLYCOMIMETICS INC
Series A-1 Preferred Stock
C - Conversion -11.824.058 0 -100,00
2014-01-15 2014-01-15 4 GLYC GLYCOMIMETICS INC
Common Stock
P - Purchase 512.500 4.093.377 14,31 8,00 4.100.000 32.747.016
2014-01-15 2014-01-15 4 GLYC GLYCOMIMETICS INC
Common Stock
C - Conversion 3.580.877 3.580.877
2014-01-03 2014-01-01 4 MM Millennial Media Inc.
Common Stock
A - Award 13.755 28.354 94,22
2013-11-18 2013-11-15 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 25.800 406.500 6,78 19,31 498.185 7.849.312
2013-11-18 2013-11-15 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 23.700 380.700 6,64 20,31 481.269 7.730.761
2013-11-18 2013-11-14 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 163.620 357.000 84,61 19,04 3.115.538 6.797.744
2013-11-18 2013-11-14 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 152.459 193.380 372,57 19,99 3.047.335 3.865.260
2013-11-18 2013-11-14 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 40.921 40.921 20,91 855.654 855.654
2013-11-13 2013-11-12 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -201.012 1.661.357 -10,79 32,37 -6.506.758 53.778.126
2013-11-13 2013-11-12 4 ECOM CHANNELADVISOR CORP
Common Stock
S - Sale -903.229 1.862.369 -32,66 32,37 -29.237.523 60.284.885
2013-09-17 2013-09-13 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other 4.815 7.944 153,88
2013-09-17 2013-09-13 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other -200.000 0 -100,00
2013-09-17 2013-09-13 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other 200.000 200.000
2013-09-17 2013-09-13 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other -20.000.000 54.184.956 -26,96
2013-08-16 2013-08-14 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other 3.129 3.129
2013-08-16 2013-08-14 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other -130.000 0 -100,00
2013-08-16 2013-08-14 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other 130.000 130.000
2013-08-16 2013-08-14 4 GRPN Groupon, Inc.
Class A Common Stock
J - Other -13.000.000 74.184.956 -14,91
2013-08-14 2013-08-14 4 CVT CVENT INC
Series A Preferred Stock
C - Conversion -7.296.582 0 -100,00
2013-08-14 2013-08-14 4 CVT CVENT INC
Common Stock
C - Conversion 7.296.582 7.296.582
2013-07-18 2013-07-18 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
D - Sale to Issuer -5.833.213 0 -100,00
2013-06-07 2013-06-05 4 EPZM Epizyme, Inc.
Series B Preferred Stock
C - Conversion -16.899.721 0 -100,00
2013-06-07 2013-06-05 4 EPZM Epizyme, Inc.
Common Stock
P - Purchase 400.000 6.033.240 7,10 15,00 6.000.000 90.498.600
2013-06-07 2013-06-05 4 EPZM Epizyme, Inc.
Common Stock
C - Conversion 5.633.240 5.633.240
2013-06-05 2013-06-04 4 TSRO TESARO, Inc.
Common Stock
J - Other 829 829
2013-06-05 2013-06-04 4 TSRO TESARO, Inc.
Common Stock
J - Other -16.450 0 -100,00
2013-06-05 2013-06-04 4 TSRO TESARO, Inc.
Common Stock
J - Other 16.450 16.450
2013-06-05 2013-06-04 4 TSRO TESARO, Inc.
Common Stock
J - Other -1.645.000 9.854.255 -14,31
2013-06-05 2013-06-03 4 CLVS Clovis Oncology, Inc.
Common Stock
J - Other 575 575
2013-06-05 2013-06-03 4 CLVS Clovis Oncology, Inc.
Common Stock
J - Other -11.399 0 -100,00
2013-06-05 2013-06-03 4 CLVS Clovis Oncology, Inc.
Common Stock
J - Other 11.399 11.399
2013-06-05 2013-06-03 4 CLVS Clovis Oncology, Inc.
Common Stock
J - Other -1.139.890 2.279.781 -33,33
2013-05-29 2013-05-29 4 ECOM CHANNELADVISOR CORP
Series C Preferred Stock
C - Conversion -44.249.588 0 -100,00
2013-05-29 2013-05-29 4 ECOM CHANNELADVISOR CORP
Series C Preferred Stock
S - Sale -95.980 44.249.588 -0,22 0,88 -83.982 38.718.390
2013-05-29 2013-05-29 4 ECOM CHANNELADVISOR CORP
Series C Preferred Stock
X - Other 122.602 44.345.568 0,28 0,68 83.982 30.376.714
2013-05-29 2013-05-29 4 ECOM CHANNELADVISOR CORP
Warrant to Purchase Series C Preferred Stock (right to buy)
X - Other -122.602 0 -100,00
2013-05-29 2013-05-29 4 ECOM CHANNELADVISOR CORP
Common Stock
C - Conversion 2.765.599 2.765.599
2013-05-23 3 ILIU INTERLEUKIN GENETICS INC
Common Stock
15.429.122
2013-04-30 2013-04-26 4 MM Millennial Media Inc.
Common Stock
A - Award 14.599 14.599
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -6.165.747 0 -100,00
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note
C - Conversion -633.219 0 -100,00
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Warrant (right to buy)
C - Conversion -156.250 0 -100,00
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
P - Purchase 625.000 5.833.213 12,00 8,00 5.000.000 46.665.704
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
C - Conversion 4.418.940 5.208.213 559,87
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
C - Conversion 633.219 789.273 405,77 8,00 5.065.752 6.314.184
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
S - Sale -196 156.054 -0,13 8,00 -1.568 1.248.432
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
C - Conversion 156.250 156.250 0,01 1.562 1.562
2013-04-11 2013-04-11 4 OMTH Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note
A - Award 633.219 633.219
2013-04-11 2013-04-11 4 OMTH Omthera Pharmaceuticals, Inc.
Warrant (right to buy)
A - Award 156.250 156.250
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class B Common Stock
C - Conversion -2.321.212 4.642.425 -33,33
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class A Common Stock
J - Other 559 1.730 47,74
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class A Common Stock
J - Other -23.212 0 -100,00
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class A Common Stock
J - Other -23.212 0 -100,00
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class A Common Stock
J - Other -2.321.212 0 -100,00
2013-04-11 2013-04-10 4 WDAY Workday, Inc.
Class A Common Stock
C - Conversion 2.321.212 2.321.212
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class B Common Stock
C - Conversion -2.321.212 4.642.425 -33,33
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class A Common Stock
J - Other 1.171 1.171
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class A Common Stock
J - Other -23.212 0 -100,00
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class A Common Stock
J - Other 23.212 23.212
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class A Common Stock
J - Other -2.321.212 0 -100,00
2013-04-11 2013-04-09 4 WDAY Workday, Inc.
Class A Common Stock
C - Conversion 2.321.212 2.321.212
2012-10-30 2012-10-29 4 MM Millennial Media Inc.
Common Stock
S - Sale -1.597.787 8.196.614 -16,31 13,44 -21.478.252 110.182.984
2012-10-18 2012-10-17 4 WDAY Workday, Inc.
Class B Common Stock
C - Conversion 6.963.636 13.927.273 100,00
2012-10-18 2012-10-17 4 WDAY Workday, Inc.
Series E Convertible Preferred Stock
C - Conversion -6.963.636 0 -100,00
2012-10-18 2012-10-17 4 WDAY Workday, Inc.
Class B Common Stock
C - Conversion 6.963.637 6.963.637
2012-10-18 2012-10-17 4 WDAY Workday, Inc.
Series E Convertible Preferred Stock
C - Conversion -6.963.637 0 -100,00
2012-09-06 2012-09-05 4 FIO FUSION-IO, INC.
Common Stock
S - Sale -64.634 0 -100,00 27,67 -1.788.494
2012-09-06 2012-09-04 4 FIO FUSION-IO, INC.
Common Stock
J - Other 1.084 3.751 40,64
2012-09-06 2012-09-04 4 FIO FUSION-IO, INC.
Common Stock
J - Other -45.000 0 -100,00
2012-09-06 2012-09-04 4 FIO FUSION-IO, INC.
Common Stock
J - Other 45.000 45.000
2012-09-06 2012-09-04 4 FIO FUSION-IO, INC.
Common Stock
J - Other -4.500.000 9.038.379 -33,24
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-1 Preferred Stock
C - Conversion -611.185 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Convertible Promissory Note
C - Conversion 0
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Convertible Promissory Note
C - Conversion 0
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Convertible Promissory Note
C - Conversion 0
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
C - Conversion -2.043 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
C - Conversion -2.043 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
J - Other -51.744 2.043 -96,20 10,00 -517.440 20.430
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
J - Other -51.744 2.043 -96,20 10,00 -517.440 20.430
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
X - Other 53.787 53.787
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
X - Other 53.787 53.787
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy)
X - Other -53.787 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy)
X - Other -53.787 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock Warrant (right to buy)
X - Other -125.291 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock
C - Conversion -898.808 0 -100,00
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
P - Purchase 500.000 2.884.221 20,97 10,00 5.000.000 28.842.210
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 177.841 2.384.221 8,06
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 180.459 2.206.740 8,91
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 434.096 2.026.281 27,26
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 2.043 1.592.185 0,13
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 2.043 1.592.185 0,13
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
J - Other -51.119 1.588.099 -3,12
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
X - Other 125.291 1.639.218 8,28
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 898.808 1.513.927 146,12
2012-08-02 2012-07-31 4 HPTX HYPERION THERAPEUTICS INC
Common Stock
C - Conversion 611.185 615.119 15.535,97
2012-07-25 3 HPTX HYPERION THERAPEUTICS INC
Common Stock
3.934
2012-07-03 2012-07-03 4 TSRO TESARO, Inc.
Series B Preferred Stock
C - Conversion -5.253.859 0 -100,00
2012-07-03 2012-07-03 4 TSRO TESARO, Inc.
Series A Preferred Stock
C - Conversion -5.134.285 0 -100,00
2012-07-03 2012-07-03 4 TSRO TESARO, Inc.
Common Stock
P - Purchase 1.111.111 11.499.255 10,70 13,50 14.999.998 155.239.942
2012-07-03 2012-07-03 4 TSRO TESARO, Inc.
Common Stock
C - Conversion 10.388.144 10.388.144
2012-05-01 2012-04-27 4 FIO FUSION-IO, INC.
Common Stock
J - Other 1.688 2.667 172,42
2012-05-01 2012-04-27 4 FIO FUSION-IO, INC.
Common Stock
J - Other -69.998 0 -100,00
2012-04-04 2012-04-03 4 MM Millennial Media Inc.
Series D Preferred Stock
C - Conversion -1.758.302 0 -100,00
2012-04-04 2012-04-03 4 MM Millennial Media Inc.
Series C Preferred Stock
C - Conversion -8.036.099 0 -100,00
2012-04-04 2012-04-03 4 MM Millennial Media Inc.
Common Stock
C - Conversion 9.794.401 9.794.401
2012-03-16 2012-03-14 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 69.998 16,67
2012-03-16 2012-03-14 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 13.538.379 -6,88
2012-03-13 2012-03-09 4 FIO FUSION-IO, INC.
Common Stock
J - Other 9.998 59.998 20,00
2012-03-13 2012-03-09 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 14.538.379 -6,44
2012-03-07 2012-03-05 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 50.000 25,00
2012-03-07 2012-03-05 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 15.538.379 -6,05
2012-03-01 2012-02-28 4 ECHO Echo Global Logistics, Inc.
Common Stock
J - Other 97 97
2012-03-01 2012-02-28 4 ECHO Echo Global Logistics, Inc.
Common Stock
J - Other -4.000 0 -100,00
2012-03-01 2012-02-28 4 ECHO Echo Global Logistics, Inc.
Common Stock
J - Other 4.000 4.000
2012-03-01 2012-02-28 4 ECHO Echo Global Logistics, Inc.
Common Stock
J - Other -400.000 2.020.219 -16,53
2012-02-29 2012-02-27 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 40.000 33,33
2012-02-29 2012-02-27 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 16.538.379 -5,70
2012-02-27 2012-02-24 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 30.000 50,00
2012-02-27 2012-02-24 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 17.538.379 -5,39
2012-02-27 2012-02-23 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 20.000 100,00
2012-02-27 2012-02-23 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 18.538.379 -5,12
2012-02-23 2012-02-21 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 10.000
2012-02-23 2012-02-21 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 19.538.379 -4,87
2012-02-14 2012-02-10 4 FIO FUSION-IO, INC.
Common Stock
J - Other 244 979 33,20
2012-02-14 2012-02-10 4 FIO FUSION-IO, INC.
Common Stock
J - Other -10.000 0 -100,00
2012-02-14 2012-02-10 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 10.000
2012-02-14 2012-02-10 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 20.538.379 -4,64
2012-02-09 2012-02-07 4 FIO FUSION-IO, INC.
Common Stock
J - Other 244 735 49,69
2012-02-09 2012-02-07 4 FIO FUSION-IO, INC.
Common Stock
J - Other -10.000 0 -100,00
2012-02-09 2012-02-07 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 10.000
2012-02-09 2012-02-07 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 21.538.379 -4,44
2012-02-06 2012-02-06 4 FIO FUSION-IO, INC.
Common Stock
S - Sale -23.083 64.634 -26,32 23,05 -532.063 1.489.814
2012-02-06 2012-02-02 4 FIO FUSION-IO, INC.
Common Stock
J - Other 491 491
2012-02-06 2012-02-02 4 FIO FUSION-IO, INC.
Common Stock
J - Other -20.000 0 -100,00
2012-02-06 2012-02-02 4 FIO FUSION-IO, INC.
Common Stock
J - Other 10.000 20.000 100,00
2012-02-06 2012-02-02 4 FIO FUSION-IO, INC.
Common Stock
J - Other -1.000.000 22.538.379 -4,25
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)